Compare Icl Group Ltd (ICL) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs Nuwellis Inc — how do they compare? Icl Group Ltd trades at $5.01 (market cap $6.47B), while Nuwellis Inc trades at $0.69 (market cap $2.20M). The key difference: Icl Group Ltd is far larger — about 2940.9× Nuwellis Inc's market cap, and Icl Group Ltd pays a 4.11% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Icl Group Ltd for 56 Days and Nuwellis Inc for 26 Days on average.
| ICL | NUWE | |
|---|---|---|
Market Cap | $6.47B | $2.20M |
Volume | 1,387,140 | 121,544 |
Sector | Basic Materials | Health |
52-Week High | $6.84 | $146.65 |
52-Week Low | $4.80 | $0.68 |
Typical Hold Time | 56 Days | 26 Days |
Enterprise Value | $9.11B | -$1.52M |
Dividend Yield | 4.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICL trades at $5.08 with no daily change, showing stable but muted short-term performance. The stock exhibits bearish technical signals with declining revenue and net income margins over recent years, though Q2 2026 earnings beat expectations. Analyst consensus is entirely neutral with 4 hold ratings and a $6.08 price target, suggesting limited near-term upside. Recent news highlights dividend stability and cost-transformation initiatives amid fertilizer industry headwinds.
ICL faces mixed prospects with stable cash flows and dividend payments offset by profitability pressures. The 19.7% upside to consensus target offers moderate potential, but investors must weigh declining margins against operational efficiency efforts. Key risks include input cost inflation and reduced fertilizer demand, requiring careful monitoring of Q3 2026 results and cost program execution.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
